Christina Fuentes, Ph.D.


Brings cutting edge cell & gene therapy experience in both gene editing and stem cells.

About Christina

Christina Fuentes is a Bioengineer with experience in gene and cell therapies. Her expertise includes synthesis and characterization of hydrogels for scalable, 3D culture of pluripotent stem cells, and in vivo genome editing using adeno-associated virus mediated delivery of CRISPR/Cas9. Christina has extensive experience in molecular cloning, viral production and purification, CRISPR/Cas9 design and application, and polymer synthesis. While earning her Ph.D. in Bioengineering at UC Berkeley, Christina’s research led to one invited review, two research papers, and one patent.

During her doctoral work, Christina also gained industry experience through a summer internship in the Antibody Engineering Department at Genentech. She conducted and analyzed experiments related to phage display screens of antigen-binding fragments. While interning, Christina was awarded a position in the Genentech Leader Intern Exchange Program (gLINX) where she met with senior leaders at the company to gain deeper knowledge about successful strategies for managing and leading teams and projects in the biotechnology industry.

Christina received her Bachelor’s in Biomedical Engineering at Northwestern University where she also has had hands-on experience in device development. In her Senior Capstone project, Christina worked in a team to build a wireless respiratory monitor for continuous measurement of respiration and detection of respiratory distress. Within a year, the project was taken from the initial brainstorming stage to human subject testing with IRB approval.

Christina is passionate about working collaboratively to develop solutions to unique challenges in the Cell and Gene Therapy field.




Multicultural Education Program and Restorative Justice Graduate Student Inclusivity Certificate Program, UC-Berkeley


Dr. Fuentes co-authored the first externally-prepared proposed draft FDA guidance, on the topic of “Proposed DRAFT guidance for FDA Consideration: Testing of Adeno-Associated Viral (AAV) Vector-Based Human Gene Therapy Products for Empty Capsids During Product Manufacture.” The proposed draft guidance, which can be found in its entirety here, aims to offer a benchmarking goal in making a recommendation to establish a release criterion for empty AAV vector capsid impurity. The guidance was formally submitted to the FDA on May 15, 2022.


University of California, Berkeley
Ph.D., Bioengineering and Biomedical Engineering

Northwestern University
B.S., Bioengineering and Biomedical Engineering

We use cookies to help give you the best experience on our website. By continuing you agree to our use of cookies.